NRBO — Neurobo Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00- $17.71m
- -$4.72m
- 28
- 31
- 52
- 30
Annual cashflow statement for Neurobo Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -21.3 | -29.7 | -15.3 | -14 | -12.5 |
| Depreciation | |||||
| Non-Cash Items | 13.5 | 18.1 | 0.686 | 3.4 | -2.73 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.744 | 0.809 | -0.584 | -1.17 | 4.4 |
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Cash from Operating Activities | -7.04 | -10.8 | -15.1 | -11.7 | -10.8 |
| Capital Expenditures | -0.214 | -0.004 | -0.003 | 0 | -0.05 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -5.84 | 0.073 | -0.583 | 0.008 | — |
| Acquisition of Business | |||||
| Sale of Business | |||||
| Sale of Fixed Assets | |||||
| Cash from Investing Activities | -6.06 | 0.069 | -0.586 | 0.008 | -0.05 |
| Financing Cash Flow Items | -0.074 | -0.695 | -2.09 | -3.57 | -0.08 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 24.2 | 6.86 | 22 | 28.7 | -0.08 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 11.1 | -3.83 | 6.3 | 17 | -10.9 |